Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Argatroban - Mitsubishi Chemical

X
Drug Profile

Argatroban - Mitsubishi Chemical

Alternative Names: Acova; Arganova; Argatra; Argipidine; Da Bei; DK 7419; Exembol; GN 1600; MCI-9038; MD 805; Novastan; OM 805; Slonnon

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Chemical
  • Developer Correvio Pharma; Daiichi Sankyo Company; Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Europe; Novartis; University of Texas Health Science Center at Houston
  • Class Anti-ischaemics; Anticoagulants; Antithrombotics; Carboxylic acids; Imines; Ischaemic heart disorder therapies; Pipecolic acids; Piperidines; Quinolines; Small molecules; Sulfones; Vascular disorder therapies
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Heparin-induced thrombocytopenia and thrombosis syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial thrombosis; Heparin-induced thrombocytopenia and thrombosis syndrome; Peripheral arterial occlusive disorders; Stroke
  • Registered Intracranial thrombosis
  • Discontinued Myocardial infarction; Unstable angina pectoris

Most Recent Events

  • 08 Apr 2021 Discontinued - Phase-II for Stroke (Combination therapy) in United Kingdom (IV) (EudraCT2012-002319-25)
  • 08 Apr 2021 Discontinued - Phase-II for Stroke (Combination therapy) in USA (IV) (NCT01464788)
  • 01 Mar 2021 Daiichi Sankyo Company plans to transfer rights of Slonnon to Alfresa Pharma by December 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top